Tower Research Capital LLC TRC Buys 43,364 Shares of Moderna, Inc. (NASDAQ:MRNA)

Tower Research Capital LLC TRC lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 260.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 60,028 shares of the company's stock after buying an additional 43,364 shares during the quarter. Tower Research Capital LLC TRC's holdings in Moderna were worth $2,496,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its position in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC boosted its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc bought a new stake in Moderna in the 4th quarter valued at about $37,000. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the 4th quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Stock Down 0.6 %

Moderna stock traded down $0.17 during mid-day trading on Friday, hitting $27.22. 7,714,270 shares of the stock were exchanged, compared to its average volume of 7,325,199. The firm's fifty day simple moving average is $30.36 and its two-hundred day simple moving average is $38.85. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The stock has a market capitalization of $10.52 billion, a price-to-earnings ratio of -2.93 and a beta of 2.23.

Analysts Set New Price Targets

A number of research firms have commented on MRNA. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada reiterated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.